Table 3.
Unadjusted Cumulative Incidence of Clinical Outcomes for Patients Discharged With Sacubitril/Valsartan Versus an ACEI/ARB
| Sacubitril/Valsartan (n=1551) | ACEI/ARB (n=7857) | P Value | |
|---|---|---|---|
| Effectiveness end points | |||
| All‐cause mortality | |||
| 30 d | 75 (4.9) | 428 (5.5) | 0.32 |
| 12 mo | 444 (29.5) | 2369 (30.9) | 0.22 |
| All‐cause hospitalization | |||
| 30 d | 356 (23.0) | 1704 (21.7) | 0.25 |
| 12 mo | 984 (64.7) | 4835 (62.6) | 0.07 |
| All‐cause mortality or HF hospitalization | |||
| 30 d | 195 (12.6) | 1035 (13.2) | 0.54 |
| 12 mo | 792 (52.3) | 3876 (50.4) | 0.18 |
| HF hospitalization | |||
| 30 d | 142 (9.2) | 652 (8.3) | 0.26 |
| 12 mo | 560 (37.0) | 2418 (31.4) | <0.001 |
| Falsification (negative control) end points | |||
| Metabolic/Nutritional hospitalization within 12 mo | 36 (2.4) | 144 (1.9) | 0.19 |
| Urinary tract infection hospitalization within 12 mo | 17 (1.1) | 100 (1.3) | 0.58 |
Data presented as n (%). Cumulative incidence of mortality and mortality or HF hospitalization end points were calculated using the Kaplan‐Meier method and group differences were evaluated using log‐rank tests. Cumulative incidence for hospitalization outcomes was estimated using the cumulative incidence function to account for the competing risk of mortality, and group differences were evaluated using Gray tests. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; and HF, heart failure.